An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.

A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.

Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.

But late-breaking data raise questions about lack of a dose response.